Last reviewed · How we verify
NCT03950011: BDD RAAC
Database for Data Collection in the Context of an Enhanced Recovery After Surgery Program in Oncology Surgery
trial testing Enhanced recovery after surgery program in Oncology in 500 participants. Status unknown.
1 January 2020
Quick facts
| Lead sponsor | Institut Paoli-Calmettes |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2016 |
| Primary completion | 1 January 2020 |
| Estimated completion | 28 February 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Enhanced recovery after surgery program
Conditions studied
- Oncology — all drugs for Oncology →
Sponsor
Institut Paoli-Calmettes — full company profile →
Who can join
18 and older, female only, with Oncology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
RETRACTED: Choosing the most appropriate minimally invasive approach to treat gynecologic cancers in the context of an enhanced recovery program: Insights from a comprehensive cancer center.
Netter A, Jauffret C, Brun C, Sabiani L, et al · · 2020 · cited 5× · PMID 32324762 · DOI 10.1371/journal.pone.0231793
Verify or expand the search:
- PubMed search for NCT03950011
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oncology
Currently open trials in the same condition.
- NCT07341464 — Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends · NA · recruiting
- NCT07262632 — Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment · recruiting
- NCT06868524 — Leading Healthy Eating and Activity Promotion Program · NA · recruiting
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
Other Institut Paoli-Calmettes trials
Trials by the same sponsor.
- NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
- NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
- NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
- NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
- NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03950011 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
- Last refreshed: 14 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03950011.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing